Nxera Pharma
Matt Barnes is an accomplished pharmaceutical executive with extensive experience in research and development, currently serving as the Executive Vice President and President of Nxera Pharma UK, as well as Head of R&D at Nxera Pharma since August 2016. Prior to this role, Matt Barnes was the Director of Pharmacology at Takeda from January 2003 to July 2016 and also held the position of Group Leader/Senior Scientist in Molecular and Cellular Systems at Celltech Ltd. (now UCB) from March 1998 to January 2003. Educationally, Matt Barnes earned a Doctor of Philosophy (PhD) in Pharmacology and a Bachelor of Science (BS) in Biochemistry, both from Newcastle University, completing studies in 1998 and 1994, respectively.
This person is not in any teams
This person is not in any offices
Nxera Pharma
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).